The Cystic Fibrosis Foundation is giving Laurent Pharmaceuticals $2 million to conduct a Phase 2 clinical trial of Laurent’s cystic fibrosis therapy LAU-7b.

The additional funding comes on top of $3 million that the foundation has already given the company.

“We are truly grateful for this additional support from Cystic Fibrosis Foundation. This will enable us to advance the LAU-7b treatment paradigm for patients with CF, and we are encouraged by the interest received from the foundation, the clinical sites and investigators,” Radu Pislariu, the president and chief executive officer of Laurent Pharmaceuticals, said in a press release.